StockNews.com Initiates Coverage on Senseonics (NYSE:SENS)

StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a report published on Saturday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Senseonics in a report on Friday.

Senseonics Price Performance

NYSE:SENS opened at $0.28 on Friday. The company has a quick ratio of 2.89, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics has a twelve month low of $0.28 and a twelve month high of $0.75. The stock’s 50-day simple moving average is $0.35 and its 200 day simple moving average is $0.40.

Institutional Investors Weigh In On Senseonics

Hedge funds have recently modified their holdings of the company. Geode Capital Management LLC raised its position in Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares during the last quarter. FMR LLC grew its holdings in shares of Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Senseonics in the third quarter valued at approximately $117,000. Symmetry Partners LLC bought a new position in Senseonics in the 3rd quarter valued at approximately $164,000. Finally, Cubist Systematic Strategies LLC boosted its position in Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after buying an additional 85,501 shares during the period. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.